A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

Clinical trial NCT07053020 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07053020
Sponsor: M.D. Anderson Cancer Center
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)

Start date: 2027-12-01
Primary completion: 2028-06-30
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.